Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.
作者信息
Sanyal Arun J, Shankar Sudha S, Calle Roberto A, Samir Anthony E, Sirlin Claude B, Sherlock Sarah P, Loomba Rohit, Fowler Kathryn J, Dehn Clayton A, Heymann Helen, Kamphaus Tania N
机构信息
Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
AstraZeneca, Gaithersburg, MD, USA.
出版信息
Nat Med. 2022 Mar;28(3):430-432. doi: 10.1038/s41591-021-01652-8.
Abstract
摘要
相似文献
1
Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.非酒精性脂肪性肝炎的非侵入性生物标志物：美国国立卫生研究院肝脏疾病生物标志物联盟项目
Nat Med. 2022 Mar;28(3):430-432. doi: 10.1038/s41591-021-01652-8.
2
Nonalcoholic fatty liver disease: a systematic review.非酒精性脂肪性肝病：系统评价。
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.
3
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的诊断和评估，包括无创生物标志物和瞬时弹性成像。
Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.
4
[Research progress of omics biomarkers for nonalcoholic fatty liver disease].[非酒精性脂肪性肝病的组学生物标志物研究进展]
Zhonghua Gan Zang Bing Za Zhi. 2021 Jun 20;29(6):604-608. doi: 10.3760/cma.j.cn501113-20200708-00382.
5
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.诊断非酒精性脂肪性肝病/非酒精性脂肪性肝炎：非侵入性检查足矣。
Liver Int. 2018 Feb;38 Suppl 1:67-70. doi: 10.1111/liv.13658.
6
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.肝活检及非侵入性诊断测试在非酒精性脂肪性肝病/非酒精性脂肪性肝炎诊断中的局限性
World J Gastroenterol. 2014 Jan 14;20(2):475-85. doi: 10.3748/wjg.v20.i2.475.
7
The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.肝活检在非酒精性脂肪性肝病中的应用：何时进行肝活检及适合哪些患者。
Clin Liver Dis. 2018 Feb;22(1):109-119. doi: 10.1016/j.cld.2017.08.006.
8
[Research advances in diagnosis of non-alcoholic fatty liver disease].非酒精性脂肪性肝病的诊断研究进展
Zhonghua Gan Zang Bing Za Zhi. 2017 Feb 20;25(2):115-118. doi: 10.3760/cma.j.issn.1007-3418.2017.02.007.
9
LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.基于 LC-MS 的脂质组学分析在鉴别非酒精性脂肪性肝炎与非酒精性脂肪肝患者中的应用。
Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):452-459. doi: 10.1016/j.hbpd.2021.05.008. Epub 2021 Jun 25.
10
Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.基层医疗医生和专科医生对非酒精性脂肪性肝炎的认知及相关实践模式
BMC Res Notes. 2016 Mar 11;9:157. doi: 10.1186/s13104-016-1946-1.
引用本文的文献
1
Non-invasive identification of steatohepatitis in patients with MASLD using a sterol and lipidomic signature.利用甾醇和脂质组学特征对代谢功能障碍相关脂肪性肝病（MASLD）患者的脂肪性肝炎进行无创识别。
J Lipid Res. 2025 Jun 20;66(8):100845. doi: 10.1016/j.jlr.2025.100845.
2
Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives.不同来源的细胞外囊泡在代谢相关脂肪性肝病中的作用：进展与展望
Front Immunol. 2025 Mar 10;16:1544012. doi: 10.3389/fimmu.2025.1544012. eCollection 2025.
3
Lipid profile and non-alcoholic fatty liver disease detected by ultrasonography: is systemic inflammation a necessary mediator?血脂谱与超声检查发现的非酒精性脂肪性肝病：全身炎症是必要的介导因素吗？
Ann Med. 2025 Dec;57(1):2480250. doi: 10.1080/07853890.2025.2480250. Epub 2025 Mar 17.
4
A multi-omic landscape of steatosis-to-NASH progression.从肝脂肪变性到非酒精性脂肪性肝炎进展的多组学全景图。
Life Metab. 2022 Dec 1;1(3):242-257. doi: 10.1093/lifemeta/loac034. eCollection 2022 Dec.
5
MASLD: What We Have Learned and Where We Need to Go-A Call to Action.MASLD：我们所学到的和我们需要去的地方——行动呼吁。
Radiographics. 2024 Nov;44(11):e240048. doi: 10.1148/rg.240048.
6
Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease.超声剪切波和瞬时弹性成像在非酒精性脂肪性肝病中的可重复性和再现性。
Radiology. 2024 Sep;312(3):e233094. doi: 10.1148/radiol.233094.
7
Combination of Waist Circumference and Circulating Levels of IGFBP-2 as a Simple Screening Tool for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease.腰围与胰岛素样生长因子结合蛋白-2循环水平联合作为早期检测代谢功能障碍相关脂肪性肝病的简单筛查工具
Diabetes Metab Syndr Obes. 2024 Sep 5;17:3335-3341. doi: 10.2147/DMSO.S466051. eCollection 2024.
8
Integrating liver endpoints in clinical trials of cardiovascular and kidney disease.将肝脏终点纳入心血管和肾脏疾病临床试验中。
Nat Med. 2024 Sep;30(9):2423-2431. doi: 10.1038/s41591-024-03223-z. Epub 2024 Sep 3.
9
Lipoprotein Lipidomics as a Frontier in Non-Alcoholic Fatty Liver Disease Biomarker Discovery.脂蛋白组学作为非酒精性脂肪性肝病生物标志物发现的前沿领域。
Int J Mol Sci. 2024 Jul 29;25(15):8285. doi: 10.3390/ijms25158285.
10
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.年龄对NIS2+™及其他用于评估肝病和检测高危代谢相关脂肪性肝病（MASH）的非侵入性血液检测的影响
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
Zotero 插件